Saoirse Byrne spends her clinical week on the parts of medicine that rarely make headlines: the medication review, the interaction check, the honest talk about what a drug can and cannot do. She reads a label the way a lawyer reads a contract, and she brings that same unhurried scrutiny to every question readers send Oracel Pharma.
She trained in general internal medicine in Dublin, completed higher training in clinical pharmacology and therapeutics, and now divides her time between an acute medical service and a hospital drugs-and-therapeutics committee. That committee work - sorting the warnings that are theoretical from the ones that put people in hospital beds - is the instinct she brings to the forum threads.
Across the erectile-dysfunction drugs she leads with the rule that keeps people out of emergency departments: never combine a PDE5 inhibitor with nitrates, whether prescribed or recreational, because the stacked fall in blood pressure can be dangerous. She repeats it whether the question is about food, brand switching or dose, because that is the mistake that matters most.
On tadalafil, sildenafil and vardenafil she refuses to crown a single winner. In registration trials the three land in the same efficacy band; the real choice is pharmacology and lifestyle. Tadalafil's long half-life buys spontaneity, sildenafil is the cheapest and most studied, and vardenafil sits in between with its own food sensitivity. She maps onset, duration, the fatty-meal effect and the visual quirk, then hands the decision to the reader and their own prescriber.
Gabapentin is where she is most careful about expectation. It genuinely helps some people with neuropathic pain and is a workhorse anticonvulsant, but she is frank about the slow titration, the drowsiness, the need to taper rather than stop abruptly, and the way its off-label use has outrun its evidence. She also flags the real respiratory risk when it is combined with opioids.
Her ivermectin answers are deliberately measured. She separates the drug's genuine, decades-deep antiparasitic record - strongyloidiasis, onchocerciasis, scabies - from the pandemic-era antiviral claims that large randomised trials did not support. When a reader mentions travel through Central Africa she walks through Loa loa screening before any dose.
She cites primary sources - the FDA label, WHO monographs, MedlinePlus and named trials - whenever a reader asks for something they can check for themselves. A forum answer that points nowhere verifiable, she thinks, is worth very little.
Every reply she writes ends the same way: this is general education from a doctor, not a treatment plan for you. When the honest answer depends on your bloods, your other medicines or an examination she cannot perform, she says so and hands you back to your own prescriber.